Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Genomic instability is a hallmark of breast cancer, contributes to tumor heterogeneity, and influences chemotherapy resistance. Although Gap 2 and mitotic checkpoints are thought to prevent genomic instability, the role of these checkpoints in breast cancer is poorly understood. Here, we assess the Gap 2 and mitotic checkpoint functions of 24 breast cancer and immortalized mammary epithelial cell lines representing four of the six intrinsic molecular subtypes of breast cancer. We found that patterns of cell cycle checkpoint deregulation were associated with the intrinsic molecular subtype of breast cancer cell lines. Specifically, the luminal B and basal-like cell lines harbored two molecularly distinct Gap 2/mitosis checkpoint defects (impairment of the decatenation Gap 2 checkpoint and the spindle assembly checkpoint, respectively). All subtypes of breast cancer cell lines examined displayed aberrant DNA synthesis/Gap 2/mitosis progression and the basal-like and claudin-low cell lines exhibited increased percentages of chromatid cohesion defects. Furthermore, a decatenation Gap 2 checkpoint gene expression signature identified in the cell line panel correlated with clinical outcomes in breast cancer patients, suggesting that breast tumors may also harbor defects in decatenation Gap 2 checkpoint function. Taken together, these data imply that pharmacological targeting of signaling pathways driving these phenotypes may lead to the development of novel personalized treatment strategies for the latter two subtypes which currently lack targeted therapeutic options because of their triple negative breast cancer status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, fostamatinib inhibits Cyclin D1 (CCND1) to produce G1 arrest in the p53 signaling pathway, while colchicine inhibits Cyclin-dependent kinase 1 (CDK1) to produce G2 arrest in the p53 signaling pathway and cell cycle pathway38 (Supplementary Fig. 4D).”
From ASGARD is a single-cell guided pipeline to aid repurposing of drugs (2023) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Self-citationNishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Self-citationIn silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803 · cited 1×
“1).(59) These gene lists were subsequently applied to an independent set of publically available clinical data containing overall survival data, clinical annotations, PAM50 subtyping assignments, and gene expression data for approximately 2000 breast cancer patients.”
MethodSignificance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 1×
“At least two of these cell lines (HCC1428 and MDA-MB-453) appeared to express low or undetectable levels of p53 despite harboring wildtype TP53 genes.(38) Only the MDA-MB-415 cell line exhibited a mutant form (Y236C) and high basal levels of p53, suggesting that p53 activation was attenuated by a mechanism other than…”
BackgroundThe genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097 · cited 2×
“These gene lists were subsequently applied to an independent set of publically available clinical data containing overall survival data, clinical annotations, PAM50 subtyping assignments, and gene expression data for approximately 2000 breast cancer patients.(45) Clinical outcome association analyses were performed us…”
Method
Research works printed but not linked: 1
- Andreassen, P. R., Skoufias, D. A. & Margolis, R. A. In Checkpoint Controls and Cancer: Activation and Regulation Protocols Vol. 2 Methods in Molecular Biology (ed Axel H. Schonthal) Ch. 15, 213-225 (Humana Press Inc., 2004).
Cited by
Carbonic Anhydrases: Role in pH Control and Cancer
Mboge, M., Mahon, B., McKenna, R., & Frost, S. (2018) · Metabolites · doi:10.3390/metabo8010019 · Cited by 281
“2 favors a suppression of apoptotic pathways [100,102].”
BackgroundCSC Radioresistance: A Therapeutic Challenge to Improve Radiotherapy Effectiveness in Cancer
Olivares-Urbano, M. A., Griñán-Lisón, C., Marchal, J. A., & Núñez, M. I. (2020) · Cells · doi:10.3390/cells9071651 · Cited by 246
“Thus, radiation exposure induces a redistribution of the cell in the cycle resulting in an accumulation of cells in the S phase [76,77].”
BackgroundAzwar, S., Seow, H. F., Abdullah, M., Faisal Jabar, M., & Mohtarrudin, N. (2021) · Biology · doi:10.3390/biology10090854 · Cited by 173
“In eukaryotic cells, cellular proliferation and division can be divided into five wellcharacterized phases; G0 (cellular quiescence), G1 (physical and organelles developments), S (DNA synthesis), G2 (protein expression production), and M (mitotic division) [63].”
BackgroundCurcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer
Farghadani, R., & Naidu, R. (2021) · Cancers · doi:10.3390/cancers13143427 · Cited by 148
Presti, D., & Quaquarini, E. (2019) · Cancers · doi:10.3390/cancers11091242 · Cited by 126
“In HR+/HER2− BC, genetic loss of RB is rare (<3%), whereas cyclin D1 is overexpressed or amplified in a significant proportion of cases [59].”
Background
Metadata
- Authors
- Bower, J. J., Vance, L. D., Psioda, M., Smith-Roe, S. L., Simpson, D. A., Ibrahim, J. G., Hoadley, K. A., Perou, C. M., & Kaufmann, W. K.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Bower, Jacquelyn J.
- ORCID
- Venue
- npj Breast Cancer
- Published
- 2017-03-31
- Volume
- 3
- Issue
- 1
- Pages
- 9-9
- ISSN
- 2374-4677 (ISSN-L)
- PMC
- PMC5445620
- OpenAlex
- W2603388361
- Cited by
- 76
- References
- 64
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 4 · 2023: 9 · 2022: 7 · 2021: 18 · 2020: 10 · 2019: 6 · 2018: 4 · 2017: 2
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- npj Breast Cancer (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UNC Libraries
- Funders
- Breast Cancer Research Foundation
- National Institutes of Health (1f32ca134155-01, ES10126, CA58223, P50-CA58223-09A1)
- National Cancer Institute (P50‐CA58223‐09A1, CA58223-09A1, P30-ES10126, CA-58223, F32 CA134155, CA 81343, P50 CA 58223, R01CA081343, T32CA106209, P50CA058223, P30CA016086)
- National Institute of General Medical Sciences (R01GM070335)
- National Institute of Environmental Health Sciences (P30ES010126)
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill (P30-CA016086)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- breast cancer, cell cycle checkpoints, genomic instability, PAM50 molecular subtypes, spindle assembly checkpoint, luminal B, basal-like breast cancer, claudin-low breast cancer, triple-negative breast cancer, gene expression signatures, chemoresistance, tumor heterogeneity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. https://app.cochat.ai/papers/10.1038/s41523-017-0009-7
- The paper
- Bower, J. J., Vance, L. D., Psioda, M., Smith-Roe, S. L., Simpson, D. A., Ibrahim, J. G., Hoadley, K. A., Perou, C. M., & Kaufmann, W. K. (2017). Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. npj Breast Cancer. https://doi.org/10.1038/s41523-017-0009-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.